In the wake of negative market reaction to Phase II data for its non-alcoholic steatohepatitis candidate, Intercept Pharmaceuticals Inc. is arguing that benefit seen in reducing fibrosis should more than counterbalance concerns about slightly increased LDL levels seen in the same study.
Intercept has seen its share price tumble since a Nov. 7 Lancet article provided the fullest picture yet of obeticholic...